ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0378

Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis

Joseph Merola1, Peter Taylor2, Andrew Bushmakin3, Joseph Cappelleri3, Pamela Young4, Rebecca Germino5 and Gil Yosipovitch6, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, New York, NY, 6University of Miami, Miami, FL

Meeting: ACR Convergence 2020

Keywords: Dermatology, Disease-Modifying Antirheumatic Drugs (Dmards), Psoriatic arthritis, quality of life, skin

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality of life (HRQoL). Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. In two Phase 3 randomized studies, patients (pts) with active PsA treated with tofacitinib experienced greater improvements in various dermatologic endpoints, compared with placebo. As pruritus is a bothersome symptom of skin disease in pts with PsA, we sought to determine how tofacitinib treatment affects pt-reported HRQoL via clinical improvements in dermatologic symptoms including itch.

Methods: Analyses used data (mean scores from Months 1 and 3) from two Phase 3 studies (OPAL Broaden [NCT01877668]; OPAL Beyond [NCT01882439]) of pts with active PsA treated with tofacitinib 5 mg twice daily or placebo; pts were tumor necrosis factor inhibitor (TNFi)-naïve or had previous inadequate response to ≥1 TNFi. All pts were treated continuously with a single conventional synthetic DMARD. Mediation modeling, a statistical method used to assess mechanisms underlying observed relationships between different variables via other explanatory variables (mediators), was applied. The mediation model included: treatment, as the independent (explanatory) binary variable (tofacitinib 5 mg BID vs placebo); HRQoL, measured by Dermatology Life Quality Index (DLQI), as the dependent (outcome) variable; and two mediators, pt-reported Itch Severity Index (ISI) and Physician’s Global Assessment of Psoriasis (PGA-PsO) (a latent variable represented by erythema, induration, and scaling). The initial model designated the treatment effect on DLQI mediated via ISI and PGA-PsO as an indirect effect, and treatment effects not attributable to ISI or PGA-PsO as a direct effect (Figure 1).

Results: Data were collected from 468 pts, pooled from both studies. In the initial model (pooled data), the effect of tofacitinib treatment on DLQI was largely mediated by itch (measured by ISI) and PGA-PsO (indirect effect) (p< 0.0001); the effect of treatment attributable to factors other than ISI and PGA-PsO (direct effect) was not statistically significant (p=0.66). Results were consistent for pooled and individual study data. Because the direct effect was small and not statistically significant, the model was re-specified to exclude the direct effect of tofacitinib treatment on DLQI. In the revised model (pooled data), 17.7% of the indirect effect of treatment on DLQI was attributable to PGA-PsO (p=0.0006) and 82.3% was attributable to itch (p< 0.0001) (Figure 2). Analyses of individual studies using the revised model gave results generally consistent with pooled data.

Conclusion: Dermatology-focused mediation modeling showed that the majority of the effect (~80%) of tofacitinib treatment on DLQI is mediated by improvements in itch, with ~20% mediated via improvements in PGA-PsO.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by Eric Comeau, CMC Connect, and funded by Pfizer Inc.


Disclosure: J. Merola, AbbVie, 1, Arena, 1, Avotres, 1, Biogen, 1, Celgene, 1, Dermavant, 1, Eli Lilly, 1, EMD Serono, 1, Janssen, 1, LEO Pharma, 5, Merck, 1, Novartis, 1, Pfizer Inc, 5, Sanofi, 1, Regeneron, 1, Sun Pharma, 1, UCB Pharma, 5; P. Taylor, Eli Lilly, 2, 5, 8, Celgene, 2, 5, 8, AbbVie, 2, 5, 8, Biogen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Celltrion, 2, 5, 8, Fresenius, 2, 5, 8, GlaxoSmithKline, 2, 5, 8, Janssen, 2, 5, 8, Nordic Pharma, 2, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, UCB, 2, 5, 8, Pfizer, 2, 5, 8, Gilead, 2, 5, 8, Galapagos, 2, 5, 8; A. Bushmakin, Pfizer Inc, 1, 2; J. Cappelleri, Pfizer Inc, 1, 2; P. Young, Pfizer Inc, 1, 3; R. Germino, Pfizer Inc, 1, 3; G. Yosipovitch, Galderma, 1, 2, Kiniksa, 1, 2, Novartis, 1, 2, Pfizer Inc, 1, 2, Regeneron-Sanofi, 1, 2, Eli Lilly, 1, Leo, 1, 2, Menlo Therapeutics, 1, 2, Sienna, 1, Trevi, 1.

To cite this abstract in AMA style:

Merola J, Taylor P, Bushmakin A, Cappelleri J, Young P, Germino R, Yosipovitch G. Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/itch-as-the-major-mediator-of-the-effect-of-tofacitinib-on-health-related-quality-of-life-in-psoriatic-arthritis-a-mediation-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/itch-as-the-major-mediator-of-the-effect-of-tofacitinib-on-health-related-quality-of-life-in-psoriatic-arthritis-a-mediation-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology